SNY Sanofi SA (ADR)

0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 3Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
Phase 3 trial to be initiated 2Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
Phase 3 trial to commence 4Q 2017.
Type 2 diabetes
Phase 3 program to be initiated 2Q 2017, with initial data due mid-late 2017.
Fitusiran (ATLAS)
Phase 3 top-line data due mid-2017.
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 data due 4Q 2017.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3 trial initiated 4Q 2016.
Type 2 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
Type 1 Diabetes
Phase 3 enrollment commenced November 2016.
Pompe disease
Phase 3 trial initiated December 2017.
Refractory Multiple Myeloma
Phase 3 data due 4Q 2017.
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Phase 3 trial to commence 2Q 2017.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
Phase 3 trial commenced 4Q 2017.
Dupixent (dupilumab)
Nasal polyps
Pivotal Phase 2/3 trial ongoing.
Cutaneous squamous cell carcinoma
Pivotal Phase 2/3 trial started in July 2016
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
Phase 2 trial to commence 1H 2017.
Non-small cell lung cancer (NSCLC)
Phase 2 trial to commence 1H 2017.
Basal cell carcinoma
Phase 2 trial to commence in 2017.
Dupixent (dupilumab)
Food Allergy
Phase 2 data due 2H 2017.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmission due 1Q 2017 with two month review cycle.
Rheumatoid arthritis

Latest News

  1. Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales
  2. EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
  3. Regulator links Sanofi epilepsy drug to child deformities
  4. ($$) Sanofi epilepsy drug caused birth defects in up to 4,100 children
  5. Sanofi Epilepsy Drug Responsible for Birth Defects in 4,100 Children, French Regulator Says
  6. Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
  7. Sanofi Genzyme hit with patent lawsuit over new eczema drug
  8. Sanofi says could buy device assets to boost diabetes
  9. Is J&J's Pharma Sales Slowdown a Warning for Other Players?
  10. Why Flexion Therapeutics' New Pain Drug Could Be a Game-Changer
  11. ($$) Actis-backed MediS Group Acquires Winthrop Pharma Senegal
  12. Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds?
  13. After Johnson & Johnson Earnings, Buy These Pharma Stocks
  14. The 7 Most Expensive Prescription Drugs in the World
  15. 5 Stocks To Profit From The Canadian Marijuana Boom
  16. Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
  17. 5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now
  18. Generics Set To Weaken This Drugmaker; Can MS Drugs Save It?
  19. ​Boston biotech Rhythm elevates Genzyme head Meeker to board chairman
  20. Geron Stock Rises after Positive Interim Update on Imetelstat